Dec 03, 2024 8:00am EST Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Nov 26, 2024 8:45am EST Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Nov 19, 2024 8:00am EST Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Nov 07, 2024 4:05pm EST Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
Nov 05, 2024 8:00am EST Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
Oct 31, 2024 8:00am EDT Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Oct 23, 2024 8:45am EDT Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Oct 15, 2024 9:07am EDT Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
Sep 23, 2024 8:00am EDT Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
